Q2 2019 FINANCIALS NOW AVAILABLE

Posted on June 30, 2019April 30, 2020 by David Goren

30 Jun

Q2 2019 financials now available under “Public Filings” section of the Vaxil website.

Attached:

FINANCIAL STATEMENTS (JUNE 30)

MANAGEMENT DISCUSSION AND ANALYSIS (JUNE 30)

This entry was posted in Annnouncements. Bookmark the permalink.

Vaxil Granted Significant US Patent For Anti-Infective Vaccines

Vaxil Bio Licenses P-Esbp for Targeted Cancer Therapy from BGN Technologies, the Technology Transfer Company of Ben-Gurion University, Israel

Vaxil Canada
First Canadian Place, 34th Floor, 100 King Street W., Toronto, Ontario. M2N 6N4 Canada

Vaxil Israel
3 Pinhas Sapir Street, 3rd Floor, Weizmann Science Park, 74140, Rehovot, Israel

Corporate

Home
About Vaxil
Vaxil Locations
Contact Us
Board & Executives
News and Updates

INVESTORS

Investor Presentations
Public Filings
News and Updates
In the Media
Video
Scientific Publications

Copyright 2022 © VAXIL BIO THERAPEUTICS | Vaxil Bio therapeutics is an Israeli biotech focused on cancer immunotherapy, based in the Weizmann Science Park in Rehovot, Israel. Vaxil is listed on the TSX-Venture as VXL

About Vaxil
TEAM
INTELLECTUAL PROPERTY
News and Updates
In the Media

Vaxil Locations
Contact Us
Subscribe